Trastuzumab Deruxtecan (T-DXd) in HER2+ mCRC

Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.

Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.

The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.

RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.

First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.

NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.